Chemomab announces positive Phase Ib results of its SPARK study testing CM-101 in NAFLD patients
Chemomab Ltd.(Israel) announced on 5 January, 2021, positive Phase Ib results of its SPARK study testing CM-101 in NAFLD patients.
For detailed information, see the below URL.
https://www.chemomab.com/uploads/pr-chemomab-spark-results.pdf
CM-101, a monoclonal antibody designed to bind and block CCL24 activity. The antibody used the STAM™ mouse model for non-clinical studies, and data showing the improvement of NASH and fibrosis in the STAM™ mouse model was published in JHEP Reports （https://www.jhep-reports.eu/article/S2589-5559(19)30158-2/fulltext）.
In the future, we believe that further clinical trial results for CM-101 will provide evidence for the STAM™ mouse model as a clinically predictive NASH model.